Canadian Securities ExchangeThe Daily Bell
#HashtagFinance

Michael Frank on the Race to Fight Infectious Diseases | #HashtagFinance

September 1, 20201 min read

CSE’s Barrington Miller chats with Michael Frank, CEO of Revive Therapeutics Ltd. (CSE:RVV) about his company’s ambitions to enter Phase 3 clinical trial protocol to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19.

With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury
from organ transplantation.

Related links
https://revivethera.com/
https://thecse.com/en/listings/life-sciences/revive-therapeutics-ltd

[buzzsprout episode=’5240746′ player=’true’]

Subscribe:  Apple Podcasts / Spotify / SoundCloud /
Stitcher / Google Podcasts / iHeart Radio / RSS

Keep Reading

Read the blog

Aug 13, 2020#HashtagFinance

Dr. Ahmad Doroudian on the Potential of a COVID-19 Treatment | #HashtagFinance

Dr. Ahmad Doroudian on the Potential of a COVID-19 Treatment, Not a Cure | #HashtagFinance The CSE’s Barrington Miller chats with Dr. Ahmad Doroudian, CEO of BetterLife Pharma Inc. (CSE:BETR), about BetterLife’s ambitions to advance on the AP-003 clinical trial programs of Altum Pharmaceuticals Inc., which includes a therapeutic pipeline consisting of three products, including…

May 5, 2020#HashtagFinance

Alan Brochstein on Surviving Cannabis Industry ‘Potholes’ in Pandemic Times

CSE’s Barrington Miller is rejoined by Alan Brochstein, founder of 420 Investor and contributor to New Cannabis Ventures, to discuss the recent issues surrounding the cannabis industry, with a specific focus on what’s happening in the United States and in the stock market. In this wide-ranging discussion, Alan shares what he thinks are the two…

Apr 8, 2020#HashtagFinance

Evan Gappelberg on the Intersection of Ecommerce and Augmented Reality

CSE’s Barrington Miller recently caught-up with NexTech AR Solutions Corp. (CSE:NTAR) CEO Evan Gappelberg to discuss his company’s current state of operations during the Coronavirus outbreak in NYC. During this discussion, Evan provides commentary on the (positive) impact that the pandemic is having on his business (1:19), how their AR (augmented reality) technology fits within…